PharmaShots | Incisive News in 3 Shots

Subscribe Now

Kiniksa

Kiniksa Entered into a Global License Agreement with Genentech to Develop and Commercialize Vixarelimab for Fibrosis

Kiniksa Entered into a Global License Agreement with Genentech to Develop and Commercialize Vixarelimab for Fibrosis

August 4, 2022

Kiniksa Collaborated with Huadong Medicine to Develop and Commercialize Arcalyst and Mavrilimumab for Autoimmune and Inflammatory Diseases

Kiniksa Collaborated with Huadong Medicine to Develop and Commercialize Arcalyst and Mavrilimumab for Autoimmune and Inflammatory...

February 23, 2022

Kiniksa Reports Results of Mavrilimumab in P-III Trial for the Treatment of COVID-19-Related ARDS

Kiniksa Reports Results of Mavrilimumab in P-III Trial for the Treatment of COVID-19-Related ARDS

December 29, 2021

PharmaShots Weekly Snapshots (Mar 15 - 19, 2021)

PharmaShots Weekly Snapshots (Mar 15 - 19, 2021)

March 19, 2021

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

March 11, 2021

Insights+: COVID-19 Healthcare News Monthly Updates - June 2020

Insights+: COVID-19 Healthcare News Monthly Updates - June 2020

June 30, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us